Novel liver-targeted insulin comparable to insulin lispro in type 1 diabetes

According to a recent study published in Diabetes Care, liver-targeted insulin delivered at mealtime and using hepatocyte-directed vesicle technology experienced a reduction in HbA1c similar to those who were assigned to insulin lispro. In addition, this reduction was accomplished with 25% less mealtime insulin and less hypoglycemia than the participants using lispro insulin experienced. 

According to researchers, HDV technology directs insulin to the liver, the organ that stores and releases insulin to the body in individuals without diabetes. This allows the insulin to behave more like naturally produced insulin, resulting in better results. 

These results were published in Healio.com on September 25th.